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ABSTRACT
Introduction Diabetes management in very young children 
remains challenging. Glycaemic targets are achieved at the 
expense of high parental diabetes management burden and 
frequent hypoglycaemia, impacting quality of life for the whole 
family. Our objective is to assess whether automated insulin 
delivery can improve glycaemic control and alleviate the 
burden of diabetes management in this particular age group.
Methods and analysis The study adopts an open- label, 
multinational, multicentre, randomised, crossover design and 
aims to randomise 72 children aged 1–7 years with type 
1 diabetes on insulin pump therapy. Following screening, 
participants will receive training on study insulin pump and 
study continuous glucose monitoring devices. Participants 
will be randomised to 16- week use of the hybrid closed- loop 
system (intervention period) or to 16- week use of sensor- 
augmented pump therapy (control period) with 1–4 weeks 
washout period before crossing over to the other arm. The 
order of the two study periods will be random. The primary 
endpoint is the between- group difference in time spent in 
the target glucose range from 3.9 to 10.0 mmol/L based 
on sensor glucose readings during the 16- week study 
periods. Analyses will be conducted on an intention- to- 
treat basis. Key secondary endpoints are between group 
differences in time spent above and below target glucose 
range, glycated haemoglobin and average sensor glucose. 
Participants’ and caregivers’ experiences will be evaluated 
using questionnaires and qualitative interviews, and sleep 
quality will be assessed. A health economic analysis will be 
performed.
Ethics and dissemination Ethics approval has been 
obtained from Cambridge East Research Ethics Committee 
(UK), Ethics Committees of the University of Innsbruck, the 
University of Vienna and the University of Graz (Austria), 
Ethics Committee of the Medical Faculty of the University 
of Leipzig (Germany) and Comité National d’Ethique de 
Recherche (Luxembourg). The results will be disseminated 
by peer- reviewed publications and conference 
presentations.
Trial registration number NCT03784027.
INTRODUCTION
Type 1 diabetes (T1D) is characterised by 
a deficiency of insulin and is caused by 
immune- mediated destruction of pancreatic 
beta- cells in genetically predisposed individ-
uals.1The incidence of T1D is increasing by 
approximately 3% annually,2 including in the 
Strengths and limitations of this study
 ► The study adopts an open- label, multinational, mul-
ticentre, randomised, crossover design, and includes 
a large group of children across multiple geograph-
ical locations.
 ► The study enrols very young children with type 1 
diabetes and assesses closed- loop insulin delivery 
over 4 months in the home setting.
 ► All participants are already pump users limiting gen-
eralisability for those on multiple daily injections.
 ► The comparator group uses sensor- augmented 
pump therapy without low glucose suspend.
 ► The study includes psychosocial assessments in-
cluding sleep quality and health economic analysis 
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youngest age group.3 Achieving tight glycaemic control 
in T1D is particularly challenging in this population 
due to high insulin sensitivity, unpredictable food intake 
and physical activity, and highly variable insulin require-
ments.4 5 Hypoglycaemia is frequently asymptomatic and 
prolonged, particularly at night- time.6–9 Caregivers’ fear 
of hypoglycaemia leads to high diabetes management 
burden, sub- optimal glycaemic control and reduced 
quality of life.10 This contributes to the majority of young 
children either failing to meet treatment guidelines 
for target glycated haemoglobin (HbA1c) below 7.0% 
(53mmol/mol),11–14 or only achieving good glycaemic 
control through frequent caregiver input leading to high 
management burden.15 16 Poorer glycaemic control and 
young age at diagnosis of T1D are associated with struc-
tural white and grey matter changes and significant differ-
ences in brain growth compared with healthy controls.17 18 
Frequent hyperglycaemia and longer duration of T1D 
increase the risk of late microvascular and macrovascular 
complications.19
Over the past decades, new technologies have 
improved management of T1D. The use of insulin pumps 
is increasing, with 60%–92% of those below the age of 
6 years using pumps.20 21 Real- time continuous glucose 
monitoring (CGM) is now widely used, providing alarms 
and facilitating responsive insulin dose adjustments.22 
CGM use is associated with reduced incidence of diabetic 
ketoacidosis and severe hypoglycaemia, but improve-
ments in HbA1c are modest.23 24 Despite increased 
technology use, optimal glycaemic control in preschool 
children remains challenging.
Automated insulin delivery systems are an emerging 
technology promising to transform management of 
T1D.25 26 Systems use real- time glucose monitoring to 
inform algorithm- directed insulin delivery via an insulin 
pump. This aims to achieve near- physiological glucose- 
responsive subcutaneous insulin delivery.27 Current 
hybrid systems continue to require user- initiated pran-
dial insulin boluses. Several hybrid closed- loop systems 
have been evaluated in children and adolescents. Results 
demonstrate improved glycaemic control, reduced risk 
of hypoglycaemia and decreased diabetes management 
burden with improvement in quality of life for children 
and caregivers.28–35 Four hybrid closed- loop systems 
are now commercially available: the 670G and 780G 
systems (Medtronic, Northridge, California, USA), the 
Control- IQ system (Tandem Diabetes Care, San Diego, 
California, USA) and the CamAPS FX app (CamDiab, 
Cambridge, UK). Evaluations of hybrid closed- loop 
systems in preschool children in the home setting have 
been limited to 3 weeks’ duration.34 Longer- term studies 
are required to assess the efficacy of closed- loop therapy 
in this particular population.
We hypothesise that the closed- loop approach using 
the Cambridge closed- loop algorithm implemented 
in the CamAPS FX app (figure 1) will increase time in 
target glucose range over 16 weeks as compared with 
sensor- augmented pump therapy in very young children 
with T1D. We will assess safety and acceptability of this 
therapy, evaluate its impact on quality of life for care-




The study adopts an open- label, multicentre, multi-
national, randomised, two- period crossover design 
contrasting closed- loop insulin delivery using the 
Cambridge closed- loop algorithm in very young chil-
dren with T1D with sensor- augmented pump therapy 
(figure 2). Participants will include children aged 1–7 
years on insulin pump therapy for a minimum of 3 
months. The study aims to randomise 72 participants, 
with each centre recruiting 8–12 participants. The two 
intervention periods will last 16 weeks each, the order of 
which will be random. There will be seven clinical sites 
across the EU (KidsAP Horizon 2020 project).
The University of Cambridge (UK) will be the coordi-
nating centre. Clinical sites include:
1. Addenbrooke’s Hospital, Cambridge University 
Hospital NHS Foundation Trust, Cambridge, UK.
2. Leeds Teaching Hospitals NHS Trust, Leeds, UK.
3. DECCP, Centre Hospitalier de Luxembourg, Grand 
Duché de Luxembourg.
4. Hospital for Children and Adolescents, University of 
Leipzig, Leipzig, Germany.
5. Department of Pediatric and Adolescent Medicine, 
Medical University of Graz, Graz, Austria.
6. Department of Pediatrics I, Medical University of Inns-
bruck, Innsbruck, Austria.
Figure 1 CamAPS FX app with Dexcom G6 sensor 
(Dexcom, San Diego, California, USA), Dana Diabecare 
RS insulin pump (Sooil Development, Seoul, Korea), and 
automatic upload capabilities to diabetes management 
system Diasend (Glooko/Diasend, Göteborg, Sweden) 
(reproduced with permission from CamDiab, Cambridge, UK).
copyright.
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7. Department of Pediatrics and Adolescent Medicine, 
Medical University of Vienna, Vienna, Austria.
Participants may be recruited from Patient Identifi-
cation Centres associated with these sites. Qualitative 
interviews with parents/guardians will be carried out by 
the University of Edinburgh (Edinburgh, UK). Health 
economics evaluation will be conducted by VYOO Agency 
(Lyon, France).
Inclusion criteria
1. Age between 1 and 7 years (inclusive).
2. T1D (WHO definition: ‘The aetiological type named 
type 1 encompasses the majority of cases which are pri-
marily due to beta- cell destruction, and are prone to 
ketoacidosis. Type 1 includes those cases attributable 
to an autoimmune process, as well as those with beta- 
cell destruction for which neither an aetiology nor a 
pathogenesis is known (idiopathic). It does not in-
clude those forms of beta- cell destruction or failure to 
which specific causes can be assigned (eg, cystic fibro-
sis, mitochondrial defects, etc).’) for at least 6 months.
3. Insulin pump user for at least 3 months.
4. Treated with rapid or ultra- rapid acting insulin ana-
logue.
5. Subject/carer is willing to perform at least two finger- 
prick blood glucose measurements per day.
6. Screening HbA1c ≤11% (97 mmol/mol) based on 
analysis from local laboratory.
7. Able to wear glucose sensor and closed- loop system 
24/7.
8. The subject/carer is willing to follow study specific in-
structions.
9. The subject/carer is willing to upload pump and CGM 
data at regular intervals.
Exclusion criteria
1. Physical or psychological disease likely to interfere 
with the normal conduct of the study.
2. Untreated coeliac disease or thyroid disease.
3. Current treatment with drugs known to interfere 
with glucose metabolism.
4. Use of closed- loop insulin delivery within the past 
2 months.
5. Known or suspected allergy to insulin.
6. Carer’s lack of reliable telephone facility for contact.
7. Parent/guardian’s severe visual or hearing 
impairment.
8. Medically documented allergy towards the adhesive 
(glue) of plasters or subject is unable to tolerate tape 
adhesive in the area of sensor placement.
9. Serious skin diseases located at places of the body cor-
responding with sensor insertion sites.
10. Sickle cell disease, haemoglobinopathy, has received 
red blood cell transfusion or erythropoietin within 3 
months prior to time of screening.
11. Plan to receive red blood cell transfusion or erythro-
poietin over the course of study participation.
12. Subject/carer not proficient in English (UK, 
Germany, Austria, Luxembourg), German (Germany, 
Austria, Luxembourg) or French (Luxembourg).
13. Additional national exclusion criteria may apply.
Study schedule
The study will consist of up to 9 visits and 11 telephone/
email contacts (tables 1 and 2). The maximum study 
duration is 11 months. At the recruitment visit, written 
informed consent will be obtained from parents/guard-
ians and a screening HbA1c will be taken. Validated 
surveys assessing participants’ and families’ quality of 
life, psychosocial function, diabetes management and 
response to their current treatment will be completed. 
Interviews with parents/guardians will gather feedback 
on their current treatment, the clinical trial and quality 
of life changes.
Pre-randomisation training and run-in
All participants and their parents/guardians will be 
trained on CGM device and study insulin pump. Compe-
tency on the use of devices will be assessed, followed by 
2–4 weeks run- in period. To assess compliance and ability 
of the parents/guardians to use the study devices safely, at 
least 8 days of CGM data must be recorded and safe use of 
the study insulin pump demonstrated during the last 14 
days of the run- in period. CGM data will be used to assess 
baseline glucose control and may be used for treatment 
optimisation.
Figure 2 Study flowchart. CGM, continuous glucose 
monitoring; HbA1c, glycated haemoglobin. copyright.
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Table 1 Schedule of study visits when closed- loop intervention precedes sensor- augmented pump therapy
Visit/contact Description





Visit 1 Recruitment visit: Consent/assent, HbA1c 
questionnaires
– 1–2 hours   
Visit 2 CGM start: CGM training, initiation of 
CGM, competency assessment
Within 2 weeks of Visit 
1 (may coincide with 
Visit 1)
2–3 hours May be repeated 
if competency not 
achieved
Visit 3 Pump start: insulin pump training, study 
pump initiation, competency assessment
Within 1 week of Visit 
2 (may coincide with 
Visit 2)
2–4 hours May be repeated 




Contact 1 Review pump settings and CGM data; 
adjustment of treatment
After 1 week of Visit 3 
(±3 days)
30 min   
Visit 4* End of run- in, adjustment of treatment, 
treatment adherence assessment
After 2–4 weeks of 
Visit 3 (minimum of 2 
weeks)
1 hour Run- in and Visit four 
may be repeated if 
non- compliant
Randomisation Immediately after 
Visit 4
  If compliant with 
pump & CGM use
CL Intervention
16 weeks
Visit 5 CL initiation: training (CL), competency 
assessment
Within 1 week of 
Visit 4
1–2 hours   
Contact 2 Follow- up after CL start Within 24 –48 hours 
after Visit 5
30 min   
Contact 3 Follow- up, review use of study devices After 1 week of Visit 5 
(±3 days)
30 min   
Contact 4 Follow- up, review use of study devices After 4 weeks of Visit 
5 (±2 weeks)
30 min   
Contact 5 Follow- up, review use of study devices After 8 weeks of Visit 
5 (±2 weeks)
30 min   
Contact 6 Follow- up, review use of study devices After 12 weeks of Visit 
5 (±2 weeks)
30 min   
Visit 6 End of first study arm: device download, 
HbA1c, questionnaires, interview
After 16 weeks of Visit 
5 (±2 weeks)
<1 hour   





Visit 7* Sensor- augmented pump therapy 
initiation: refresher training
After 1–4 weeks of 
Visit 6 (minimum of 
1 week)
1–2 hours   
Contact 7 Follow- up after Sensor- augmented pump 
therapy start
within 24 to 48 hours 
after Visit 7
30 min   
Contact 8 Follow- up, review use of study devices After 1 week of Visit 7 
(±3 days)
30 min   
Contact 9 Follow- up, review use of study devices After 4 weeks of Visit 
7 (±2 weeks)
30 min   
Contact 10 Follow- up, review use of study devices After 8 weeks of Visit 
7 (±2 weeks)
30 min   
Contact 11 Follow- up, review use of study devices After 12 weeks of Visit 
7 (±2 weeks)
30 min   
Visit 8 (caregiver 
only) (UK and 
Luxembourg only)
Sleep assessment After 12 weeks of Visit 
7 (±2 weeks) (Visit 8 
may coincide with 
Contact 11)
30 min   
Visit 9 End of study, return and download 
of devices, HbA1c, questionnaires, 
interview, resume standard pump therapy
After 16 weeks of Visit 
7 (±2 weeks)
<1 hour   
*Could be done via phone/email.
CGM, continuous glucose monitoring device; CL, closed- loop system; HbA1c, glycated haemoglobin.
copyright.
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Table 2 Schedule of study visits when sensor- augmented pump therapy precedes closed- loop intervention
Visit/contact Description
Start relative to previous/
next Visit/activity Duration Comment
Consent and 
training
Visit 1 Recruitment visit: Consent/assent, 
HbA1c, questionnaires
– 1–2 hours   
Visit 2 CGM start: CGM training, initiation 
of CGM, competency assessment
Within 2 weeks of Visit 1 
(may coincide with Visit 1)
2–3 hours May be repeated 
if competency not 
achieved
Visit 3 Pump start: insulin pump training, 
study pump initiation, competency 
assessment
Within 1 week of Visit 2 
(may coincide with Visit 2)
2–4 hours May be repeated 




Contact 1 Review pump settings and CGM 
data; adjustment of treatment
After 1 week of Visit 3 (±3 
days)
30 min   
Visit 4* End of run- in, adjustment of 
treatment, treatment adherence 
assessment
After 2–4 weeks of Visit 3 
(minimum of 2 weeks)
1 hour Run- in and Visit four 
may be repeated if 
non- compliant
Randomisation Immediately after Visit 4 If compliant with 





Visit 5 Sensor- augmented pump therapy 
initiation: refresher training
Within 1 week of Visit 4 1–2 hours   
Contact 2 Follow- up after sensor- augmented 
pump therapy start
Within 24–48 hours after 
Visit 5
30 min   
Contact 3 Follow- up, review use of study 
devices
After 1 week of Visit 5 (±3 
days)
30 min   
Contact 4 Follow- up, review use of study 
devices
After 4 weeks of Visit 5 (±2 
weeks)
30 min   
Contact 5 Follow- up, review use of study 
devices
After 8 weeks of Visit 5 (±2 
weeks)
30 min   
Contact 6 Follow- up, review use of study 
devices
After 12 weeks of Visit 5 
(±2 weeks)
30 min   
Visit 6 End of first study arm: device 
download, HbA1c, questionnaires, 
interview
After 16 weeks of Visit 5 
(±2 weeks)
<1 hour   
Washout period (1–4 weeks)
CL Intervention
16 weeks
Visit 7* CL initiation: training (CL), 
competency assessment
After 1–4 weeks of Visit 6 
(minimum of 1 week)
1–2 hours   
Contact 7 Follow- up after CL start within 24–48 hours after 
Visit 7
30 min   
Contact 8 Follow- up, review use of study 
devices
After 1 week of Visit 7 (±3 
days)
30 min   
Contact 9 Follow- up, review use of study 
devices
After 4 weeks of Visit 7 (±2 
weeks)
30 min   
Contact 10 Follow- up, review use of study 
devices
After 8 weeks of Visit 7 (±2 
weeks)
30 min   
Contact 11 Follow- up, review use of study 
devices
After 12 weeks of Visit 7 
(±2 weeks)
30 min   
Visit 8 
(caregiver 
only) (UK and 
Luxembourg 
only)
Sleep assessment After 12 weeks of Visit 7 
(±2 weeks) (Visit 8 may 
coincide with Contact 11)
30 min   
Visit 9 End of study, return and 
download of devices, HbA1c, 
questionnaires, interview, resume 
standard pump therapy
After 16 weeks of visit 7 
(±2 weeks)
<1 hour   
*Could be done via phone/email.
CGM, continuous glucose monitoring device; CL, closed- loop system; HbA1c, glycated haemoglobin.
copyright.
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Randomisation
Eligible subjects will be randomised after run- in using 
remote central randomisation software to the initial use 
of the hybrid closed- loop system or to sensor- augmented 
pump therapy for 16 weeks, with 1–4 weeks washout period 
before crossing over to the other study arm. Randomisa-
tion will be stratified by site and the randomisation ratio 
will be 1:1 within each stratum. The randomisation list 
created by the study statistician is encrypted.
Post-randomisation training
Automated closed-loop insulin delivery (intervention arm)
Participants randomised to the closed- loop arm and their 
parents/guardians will receive a training session by the 
research team covering the use of the closed- loop system 
prior to starting closed- loop insulin delivery. Competency 
on the use of closed- loop system will be assessed. Partici-
pants will use the hybrid closed- loop system for 16 weeks 
at home.
Sensor-augmented pump therapy (control arm)
Participants in the sensor- augmented pump therapy arm 
and their parent/guardians will receive refresher training 
on key aspects of insulin pump therapy and CGM use. 
CamAPS FX app does not implement a low glucose 
suspend or predictive low glucose suspend function in 
open loop. Participants will use sensor- augmented pump 
therapy for 16 weeks at home.
Assessments at 4 and 8 months
A blood sample for HbA1c measurement will be taken 
at the end of each study arm. Validated surveys evalu-
ating the impact of devices employed on quality of life, 
psychosocial function, diabetes management and treat-
ment satisfaction will be completed. Parents/guardians 
will be invited to be interviewed to gather feedback on 
their current treatment, the clinical trial and quality of 
life changes.
Participants will have 1–4 weeks washout period before 
commencing the second study arm with training as 
described above.
In a subset of clinical sites, parents/guardians will be 
invited to participate in a parallel 7- day sleep substudy 
prior to the final study visit. All parents/guardians will 
wear an Actiwatch and keep a sleep diary. Questionnaires 
assessing sleep quality will be completed by the parents/
guardians. At the final visit, participants will resume usual 
care using their prestudy insulin pump.
Contacts during home study period
Parents/guardians will be contacted 24 hours after 
starting each study arm to ensure there are no concerns 
regarding study devices. In between study visits, parents/
guardians will be contacted by the study team by email/
telephone once monthly to record any adverse events, 
device deficiencies, changes in insulin settings, other 
medical conditions and/or medications.
Routine clinical care will be provided by the local paedi-
atric diabetes team as per usual care. Throughout the 
trial, parents/guardians and/or the clinical team are free 
to adjust insulin therapy as per usual clinical practice, but 
no active treatment optimisation or remote monitoring 
will be undertaken by the study team.
In case of any problems related to the technical device 
or diabetes management parents/guardians will be able 
to contact a 24- hour telephone helpline to the local 
research team. The local research team will have access to 
a central helpline for technical issues.
Withdrawal criteria
A participant/guardian may terminate participation in 
the study at any time without giving a reason and without 
any personal disadvantage. An investigator can stop 
the participation of a subject after consideration of the 
benefit/risk ratio. Possible reasons are:
 ► Serious adverse events.
 ► Significant protocol violation or non- compliance.
 ► Decision by the investigator, or the sponsor, that 
termination is in the subject’s best medical interest.
 ► Allergic reaction to insulin.
STUDY PROCEDURES
Blood samples
A blood sample for the measurement of HbA1c levels 
will be taken at three time points: baseline and at the 
end of each study arm. HbA1c will be measured locally 
using International Federation of Clinical Chemistry and 
Laboratory Medicine aligned methods. All HbA1c testing 




Parents/guardians will be invited to complete a series of 
validated questionnaires on health- related quality of life 
at baseline and at the end of each study arm. All question-
naires are available in English, French and German. At the 
end of the closed- loop intervention arm, parents’/guard-
ians’ experience using closed- loop will be documented 
using the parent closed- loop experience questionnaire.
Measures of sleep quality
Quality, duration and fragmentation of sleep will be 
assessed subjectively using the Pittsburgh Sleep Quality 
Index (PSQI), the Children’s Sleep Habit Questionnaire 
(CSHQ) and the Epworth sleepiness scale (ESS). Parents/
guardians will wear an Actiwatch (Philips Respironics, 
Bend, Oregon, USA) to provide objective measures 
of sleep and wakefulness based on motor activity and 
complete a sleep diary. These measures will be evaluated 
over 7 days prior to the end of the study in both arms.
Qualitative interviews
A subset of approximately 30 parents/guardians will be 
interviewed at the end of each study arm with representa-
tion from each study country and participant age- group. 
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The interviews will explore parents’/guardians’ experi-
ences of using closed- loop insulin delivery (as compared 
with sensor- augmented pump therapy) to manage their 
child’s diabetes. The same parents/guardians will be 
interviewed after completing each study arm to look at 
whether, in what ways and why, use of a closed- loop system 
(as compared with sensor- augmented pump therapy) has 
impacted on their diabetes management practices, their 
worries and concerns about hyperglycaemia and hypo-
glycaemia, and their work and family lives. Interviews 
will explore participants’ likes and dislikes of using the 
closed- loop system and how the technology might be 
improved for future use. Interviews will take place at a 
time chosen by the participant and carried out by tele-
phone. Participants will be interviewed in English or 
German by an experienced qualitative researcher fluent 
in both languages. All interviews will be transcribed in 
full for in- depth analysis; with interviews undertaken in 
German translated into English.
HEALTH ECONOMICS
Health economics analysis will be performed contrasting 
closed- loop and sensor- augmented pump therapy using 
a health economic simulation model: the IQVIA Core 
Diabetes Model (CDM; QVIA, Basel, Switzerland). The 
CDM is a validated non- product- specific policy analysis 
tool for cost- effectiveness analysis in T1D. Long- term 
outcomes derived from the simulation will include 
total direct costs, life expectancy, quality- adjusted life 
expectancy and time to onset of complications. Incre-
mental costs versus incremental effectiveness (quality- 
adjusted life years (QALYs)) for closed- loop versus sensor 
augmented pump therapy will be compared. Baseline 
characteristics of the simulation cohort will come from 
the study. Treatment effects will be based on the study 
findings comparing 16 weeks of closed- loop with 16 weeks 
of sensor- augmented pump therapy. Country- specific 
direct costs will be sourced from published literature and 
where necessary inflated to the current year costs. For 
treatment costs, only the incremental costs between the 
two interventions will be considered.
PATIENT AND PUBLIC INVOLVEMENT
The research question and study endpoints are based on 
feedback from participants of previous studies and in line 
with prioritisation by stakeholders. The study design and 
assessment of burden of the intervention were reviewed 
by focus groups. Results will be disseminated to partici-
pants and the general public through social media and 
made available on the sponsor’s website.
STATISTICAL ANALYSIS
All analyses will be conducted on an intention- to- treat 
basis. Data from all randomised participants with/without 
protocol violation including drop- outs and withdrawals 
will be included in the analysis. The statistical analysis 
plan can be found in online supplemental information.
Primary endpoint analysis
The primary analysis will evaluate the between group 
difference in time spent in the target glucose range from 
3.9 to 10.0 mmol/L based on CGM glucose levels during 
the 16- week study periods. Mean±SD or summary statis-
tics appropriate to the distribution will be reported for 
the primary endpoint over the 16- week period by treat-
ment intervention. The treatment interventions will be 
compared using a linear mixed model adjusting for period 
as a fixed effect and site as a random effect. The model 
will account for correlated data from the same subject. 
A 95% CI will be reported for the difference between 
the interventions based on the linear mixed model. The 
primary analysis will be a single statistical comparison of a 
single outcome measure.
Key secondary endpoints
For the following key endpoints, the familywise type I error 
rate will be controlled at two- sided α=0.05. A gatekeeping 
strategy will be used, where the primary endpoint will be 
tested first, if passing the significance testing, other key 
endpoints will be tested in the order listed below using 
the fixed- sequence method at α=0.05.
 ► Time spent in target glucose range (3.9 to 
10.0 mmol/L).
 ► Time spent above target glucose (10.0 mmol/L).
 ► HbA1c.
 ► Average of glucose levels.
 ► Time spent below target glucose (3.9 mmol/L).
Secondary efficacy endpoints
The following endpoints will be assessed:
CGM derived indices:
 ► SD and coefficient of variation of glucose levels.
 ► Time with glucose levels <3.0 mmol/L.
 ► Time with glucose levels in significant hyperglycaemia 
(glucose levels>16.7 mmol/L).
 ► AUC of glucose below 3.5 mmol/L.
Insulin dose and other endpoints:
 ► Body mass index (BMI) SD score.
 ► Total, basal and bolus insulin dose.
For all secondary endpoints, summary statistics 
appropriate to the distribution will be tabulated by 
treatment group. Analysis of all secondary CGM and 
insulin endpoints will parallel the primary analysis. For 
these exploratory analyses, the Benjamini- Hochberg 
false discovery rate will be used to account for multiple 
comparisons. The models comparing BMI SD score and 
HbA1c will also adjust for baseline value at the start of 
each period. A ranked normal score transformation will 
be applied to all highly skewed secondary endpoints.
Summary statistics for the following outcome metrics 
will also be tabulated separately for daytime (defined 
as 8:00 hours to less than 24:00 hours) and night- time 
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(defined as 00:00 hours to less than 8:00 hours) over the 
16- week period:
 ► Percent time with glucose levels spent in the target 
range (3.9 to 10.0 mmol/L).
 ► Mean of glucose levels.
 ► SD of glucose levels.
 ► Per cent time with glucose levels below 3.9 mmol/L.
 ► Total insulin dose.
Safety analysis
The following events will be recorded and compared 
between study arms:
 ► Number of subjects with any diabetic ketoacidosis 
events.
 ► Number of episodes of diabetic ketoacidosis events 
per subject and incidence rate per 100 person- years.
 ► Number of subjects with any severe hypoglycaemia 
events.
 ► Number of episodes of severe hypoglycaemia events 
per subject and incidence rate per 100 person- years.
 ► Number of any other adverse events per subject.
 ► Number of any other serious adverse events per 
subject.
All safety outcomes will be tabulated for all subjects, 
including dropouts and withdrawals, regardless of 
whether CGM data are available and irrespective of 
whether closed- loop was operational. All adverse events 
will be listed for the entire study duration, including 
run- in and washout period. For diabetic ketoacidosis 
and severe hypoglycaemia events, the event rates will be 
compared using a repeated measures Poisson regression 
model adjusting for study arm. Binary safety outcomes 
will also be compared using a repeated measures logistic 
regression model adjusting for study arm.
Utility evaluation
The following system use will be tabulated:
 ► Percentage of time CGM is used for each 16- week 
treatment period.
 ► Percentage of time when closed- loop system use is 
functioning during the closed- loop period
Psychosocial evaluation
Questionnaires
For each questionnaire (and their corresponding 
subscales), total scores will be calculated and reported 
at each time point. They will also be compared between 
treatment periods using the same model described for the 
primary endpoint. The distribution of responses for each 
individual question at each time point will be reported in 
a separate table.
Sleep quality
The PSQI, CSHQ, ESS and actigraph data will be used to 
calculate mean total sleep quality score, sleep duration 
(sum of all epochs scored as sleep during the time in bed) 
and variability across nights, time in bed, sleep distur-
bance (including wake after sleep onset and number 
of awakenings), latency, efficiency, quality and daytime 
dysfunction. Sleep data will be averaged across nights in 
each parent/guardian for the parallel study period.
Qualitative interviews
To maximise rigour at least two experienced qualita-
tive researchers will be involved in data analysis using a 
thematic approach. NVivo V.11, a qualitative data analysis 
software, will be used to facilitate data management.
Health economics
For each simulation, a simulated cohort of 1000 patients 
will be run through the model 1000 times using first- 
order Monte Carlo simulation. Long- term outcomes 
derived from simulation will include total direct costs, life 
expectancy, quality- adjusted life expectancy and time to 
onset of complications. Future costs and clinical benefits 
will be discounted based on each country’s recommenda-
tions. Incremental costs versus incremental effectiveness 
(QALY) of the two therapies will be compared.
Additional exploratory health economic analysis will be 
conducted on other endpoints such as, but not limited to, 
sleep disorders and indirect costs for society.
Interim analysis
No formal interim analyses or stopping guidelines are 
planned for this study.
Power calculation
Data from the SENCE study (Strategies to Enhance New 
CGM Use in Early Childhood study, NCT02912728) were 
used to estimate the SD of the primary endpoint. Based 
on data from this study, 65 subjects are required to attain 
90% power to detect a difference if a treatment effect of 
5%, an SD of 10.3% for an individual measurement, and 
a correlation of 0.3 between periods are assumed. Adding 
an additional 10% to this sample size to account for 
drop- outs, results in a final sample size of 72 randomised 
participants.
STUDY MANAGEMENT
Composition of study management groups is shown in 
online supplemental appendix.
Data and safety monitoring board
An independent data and safety monitoring board 
(DSMB) will be informed of all serious adverse events and 
unanticipated adverse device effects that occur during the 
study. The DSMB will review compiled adverse event data 
at periodic intervals and will report to the trial steering 
committee (TSC) any safety concerns and recommenda-
tions for suspension or early termination of the trial.
Study sponsor
The study sponsors are the Cambridge University 
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Trial steering committee
The TSC will provide the overall supervision of the clinical 
trial. The TSC will comprise an independent chairperson, 
the chief investigator and leaders of work packages (WP2 
(pilot study), WP3 (main study) and WP4 (data manage-
ment)) of the KidsAP consortium. The TSC will monitor 
clinical trial progress and advise on scientific credibility. 
The TSC will consider and act, as appropriate, on the 
recommendations of the DSMB. The TSC will report its 
decisions to the Ethical Board and the General Assembly 
of the KidsAP Consortium.
Trial management group
The trial management group will meet weekly and will be 
responsible for day- to- day management of the trial.
Data management and monitoring
The study coordinators will be responsible for maintaining 
quality assurance and quality control systems to ensure 
that the trial is conducted and data are generated, docu-
mented and reported in compliance with the protocol, 
good clinical practice and regulatory requirements.
Confidentiality of participant data shall be observed 
at all times. Personal details for each participant taking 
part with a link to a unique identification number will be 
held locally on a study screening log in the trial site file at 
each study site. These details will not be revealed at any 
other stage during the study, and all results will remain 
anonymous.
Case report forms will be used for recording anony-
mised study data and will be completed in accordance with 
Good Clinical Practice and ISO 15197: 2013 guidelines.
Indemnity
Indemnity for any harm arising from the conduct of 
research will be provided according to local arrange-
ments in respective centres.
 ► Cambridge, UK- National Health Service (NHS) 
indemnity cover will apply for any claims arising from 
management and conduct of research. Any liability 
arising from study design will be covered by the clin-
ical trial insurance policy organised by the University 
of Cambridge.
 ► Graz, Innsbruck, Vienna, Austria—Subjects will be 
insured according to Medical Device Law § 47 (StF: 
BGBl. Nr. 657/1996, BGBl. I Nr. 143/2009)
 ► Leipzig, Germany—Subjects will be insured according 
to the German Medical Device Law (MPG). Any 
liability arising from the study will be covered by the 
clinical trial insurance policy organised by the Univer-
sity of Leipzig.
 ► Luxembourg—Centre Hospitalier de Luxembourg 
indemnity will apply for any claims arising from the 
management and conduct of research. Any liability 
arising from the study design will be covered by the 
clinical trial insurance policy organised by the Centre 
Hospitalier de Luxembourg (Amlin Corporate Insur-
ance NV).
ETHICS AND DISSEMINATION
This study has received approvals from the Cambridge 
East Research Ethics Committee in the UK (18/EE/0290), 
the Ethics Committee of the University of Innsbruck in 
Austria (EK Nr 1238/201), the Ethics Committee of the 
University of Vienna in Austria (EK Nr 1979/2018), the 
Ethics Committee of the University of Graz in Austria 
(EK Nr 31–077 ex 18/19), the Ethics Committee of the 
Medical Faculty of the University of Leipzig in Germany 
(029/19- ff), the Comité National d’Ethique de Recherche 
in Luxembourg (201812/01) and has undergone review 
and approval by regulatory authorities in the UK by the 
Medicines and Healthcare products Regulatory Agency, 
in Austria by the Austrian Medicines and Medical Devices 
Agency, in Germany by Bundesinstitut für Arzneimittel 
und Medizinprodukte, and in Luxembourg by the 
Ministry of Health.
All parents/guardians will be provided with oral and 
written information about the trial and study procedures 
before obtaining written informed consent. Standard 
operating procedures for monitoring and reporting of all 
adverse events and adverse device effects will be in place 
including serious adverse events, serious adverse device 
effects and specific adverse events such as severe hypo-
glycaemia and significant hyperglycaemia with ketosis. 
Any substantial amendments to the protocol and other 
documents shall be notified to and approved by the 
independent REC and the regulatory authorities, prior 
to implementation as per nationally agreed guidelines. 
Screening and recruitment commenced in May 2019, and 
the study is expected to be completed by June 2021. Study 
results will be disseminated by peer- reviewed publications 
and conference presentations.
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